Objective: To evaluate the impact of age on recovery from multiple sclerosis relapses.
Background: Increasing disability in multiple sclerosis is a consequence of progressive disease and incomplete relapse recovery.
Methods: The first and last-ever relapse data (357 relapses in 193 patients) from the Olmsted County population-based multiple sclerosis cohort were systematically reviewed for age, fulminance, location (optic nerve, brainstem/cerebellar, spinal cord), peak deficit, and maximum recovery. Three different relapse-outcome measures were studied both as paired analyses and as an overall group effect: change from peak deficit to maximum recovery in raw functional system score related to the relapse (ΔFSS), a previously published FSS-based relapse-impact model, and change from peak deficit to maximum recovery in Extended Disability Status Scale (ΔEDSS) score.
Results: Older age was linearly associated with worse recovery in the ΔFSS outcome ( = 0.002), ΔEDSS outcome ( < 0.001), and the FSS-based relapse-impact model ( < 0.001). A multivariate analysis of ΔFSS outcome linked poor recovery to older age ( = 0.015), relapse location (transverse myelitis or brainstem/cerebellar syndrome; < 0.001), and relapse fulminance ( = 0.004).
Conclusion: Multiple sclerosis-relapse recovery declines in a linear fashion with increased age, which should be considered when making treatment decisions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1352458518800815 | DOI Listing |
PLoS One
January 2025
Department of Epidemiology, Epidemiology Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Background: Multiple sclerosis (MS) onset is caused by genetic and environmental factors. Vitamin D has been identified as contributing environmental risk factor, with higher prevalence at latitudes further from the equator. Mongolia, at 45°N, has limited sunlight exposure, increasing the population's risk for vitamin D deficiency.
View Article and Find Full Text PDFCNS Neurosci Ther
January 2025
Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Multiple sclerosis (MS) is an autoimmune disorder affecting the central nervous system, with varying clinical manifestations such as optic neuritis, sensory disturbances, and brainstem syndromes. Disease progression is monitored through methods like MRI scans, disability scales, and optical coherence tomography (OCT), which can detect retinal thinning, even in the absence of optic neuritis. MS progression involves neurodegeneration, particularly trans-synaptic degeneration, which extends beyond the initial injury site.
View Article and Find Full Text PDFActa Parasitol
January 2025
Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, P.O. Box: 9453155166, Bojnurd, Iran.
Pourpose: This study aimed to investigate the seroepidemiological status of Toxoplasma gondii (T. gondii) infection in Multiple Sclerosis (MS) patients compared to controls.
Methods: The present study included 98 MS patients and 100 controls.
Toxins (Basel)
January 2025
Unité des Toxines Bactériennes, Institut Pasteur, Université Paris Cité, CNRS UMR 2001 INSERM U1306, 75015 Paris, France.
Multiple sclerosis (MS) is a chronic immune-mediated neurological disorder, characterized by progressive demyelination and neuronal cell loss in the central nervous system. Many possible causes of MS have been proposed, including genetic factors, environmental triggers, and infectious agents. Recently, epsilon toxin (ETX) has been incriminated in MS, based initially on the isolation of the bacteria from a MS patient, combined with an immunoreactivity to ETX.
View Article and Find Full Text PDFJ Funct Biomater
January 2025
School of Mechanical Engineering, School of Basic Science, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Autoimmune diseases present complex therapeutic challenges due to their chronic nature, systemic impact, and requirement for precise immunomodulation to avoid adverse side effects. Recent advancements in biodegradable and stimuli-responsive nanomaterials have opened new avenues for targeted drug delivery systems capable of addressing these challenges. This review provides a comprehensive analysis of state-of-the-art biodegradable nanocarriers such as polymeric nanoparticles, liposomes, and hydrogels engineered for targeted delivery in autoimmune therapies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!